All News Leo Acquisitions Corp Toronto S.E.

Equities

LEQ.H

CA5263612098

End-of-day quote Toronto S.E. Other stock markets 04:30:00 24/11/2023 am IST			5-day change	1st Jan Change
0.01 ^CAD	+33.33%		-.--%	-.--%

2021	PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	CI
2021	PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PsyBio Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones	31/21/31	AQ
PsyBio Therapeutics : Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	16/21/16	AQ
PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	16/21/16	CI
PsyBio Therapeutics : Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio	04/21/04	AQ
PsyBio Therapeutics : CEO and CMO to Participate in Fireside Chat at LifeSci Partners Summer Symposium	20/21/20	AQ
PsyBio Therapeutics : Announces Uplisting to OTCQB Venture Market	14/21/14	AQ
PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO	13/21/13	MT
PsyBio Therapeutics : Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent	13/21/13	AQ
PsyBio Therapeutics : Announces TSXV Approval of Share Buyback Program	28/21/28	AQ
Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds	22/21/22	CI
PsyBio Therapeutics : Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie	22/21/22	AQ
PsyBio Therapeutics Corp. Announces Executive Changes	01/21/01	CI
PsyBio Therapeutics Corp.'s Board intends to launch an Equity Buyback.	01/21/01	CI
PsyBio Therapeutics : Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors	21/21/21	AQ
PsyBio Therapeutics : Retains KCSA Strategic Communications for Investor Relations Services	09/21/09	AQ
PsyBio Therapeutics : Strengthens Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	05/21/05	MT
PsyBio Therapeutics : Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	05/21/05	AQ
PsyBio Therapeutics Announces Retention of Market Maker	04/21/04	GL
PSYO THER : PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization	02/21/02	AQ
PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.	02/21/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Leo Acquisitions Corp Toronto S.E.

Equities

LEQ.H

CA5263612098

All News

Filters